Securities Law

Facing a shareholder revolt after a damning indictment, Supermicro launches a major probe into a $2.5B shadow trade scheme. Is it too little, too late?

The new algorithm aims to systematically filter out harmful interactions and reduce hidden trading costs in the complex world of off-exchange trading.

With new clinical trial data showing its AI is superior for complex AFib, Volta Medical heads to a major conference to change the standard of care.

Willow Lane's merger with AI cloud provider Boost Run is on hold pending SEC approval, highlighting regulatory hurdles in the high-stakes GPU compute race.

American Ventures publicizes support from 85+ investors, a move to counter a recent fraud lawsuit and an ongoing SEC investigation into its practices.

An ETF offers retail investors a ticket to SpaceX's massive IPO, but a bitter public dispute with critics raises questions about transparency and risk.

The firm's top spot in the Dallas Business Journal ranking highlights its regional dominance, but what does it mean for local investors and the DFW economy?

Venture capital leaders and national security experts caution that drug pricing controls and regulatory hurdles could cede America's biomedical edge to rivals.

As AI and tech lawsuits surge, a specialized list of legal experts emerges to handle complex disputes beyond the courtroom. Here's why it matters.

A shocking $178M charge-off sends goeasy Ltd. shares plummeting, erasing billions in value and triggering a probe by a leading securities law firm.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

Landmark recommendations give universities a legal and practical roadmap to support students with celiac disease, reshaping disability access on campus.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

In a strategic move to tackle space debris, Applied Aerospace & Defense buys Vestigo, whose Spinnaker drag sails offer a solution to new regulations.

Regulators worldwide are issuing alerts against BG Wealth Sharing, an AI-themed crypto scheme luring investors with fake promises and trapping funds.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

Top policymakers, including Dr. Agustín Carstens and FATF President Luis Urrutia Corral, will convene in Mérida to address critical cross-border tax issues.

A new class action lawsuit alleges Paysafe misled investors about major client risks and industry vulnerabilities, leading to a massive 27% stock drop.

As Churchill Capital XI's shares and warrants begin separate trading, what does this mean for investors and the hunt for Michael Klein's next big deal?